Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint
25 juil. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Company’s novel drug development program AM-411 builds on positive animal dataTreatments for rheumatoid arthritis represent the second largest therapeutic area globally AM-411 to run concurrently...
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy
19 juil. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary delivery...